BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) reported Q1 EPS of ($0.04), $0.06 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $109.46 million versus the consensus estimate of $103.8 million.

Earnings